TXGHIGH SIGNALFINANCIAL10-K

TXG delivered a dramatic operational turnaround with revenue increasing 302% and operating cash flow swinging from $6.7M to $136.1M while significantly reducing net losses.

This represents a fundamental transformation in TXG's financial performance, with the company achieving substantial revenue growth while dramatically improving cash generation and profitability metrics. The massive improvement in operating cash flow combined with reduced losses suggests the business model is gaining significant traction and operational efficiency.

Comparing 2026-02-13 vs 2025-02-13View on EDGAR →
FINANCIAL ANALYSIS

TXG experienced explosive growth with revenue surging 302% to $245.9M while operating cash flow increased nearly 20-fold to $136.1M, indicating strong operational momentum and cash conversion. Net losses improved substantially from -$182.6M to -$43.5M, and the company reduced working capital with accounts receivable declining 47% and inventory falling 32%. Despite increased liabilities of 18%, the overall financial picture signals a company achieving significant scale and operational leverage, though investors should monitor the 31% increase in current liabilities for potential liquidity implications.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+1941.6%
$6.7M$136.1M

Operating cash flow surged 1941.6% — exceptional cash generation, highest quality earnings signal.

Revenue
P&L
+301.7%
$61.2M$245.9M

Strong top-line growth of 301.7% — accelerating demand or successful expansion into new markets.

Interest Expense
P&L
-93.1%
$476K$33K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Net Income
P&L
+76.2%
-$182.6M-$43.5M

Net income grew 76.2% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+68.7%
-$194.6M-$61.0M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Capital Expenditure
Cash Flow
-52.1%
$12.4M$5.9M

Capex reduced 52.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Accounts Receivable
Balance Sheet
-46.5%
$87.9M$47.0M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Inventory
Balance Sheet
-32.2%
$83.1M$56.3M

Inventory drawn down 32.2% — strong sell-through or deliberate destocking; watch for supply constraints.

Current Liabilities
Balance Sheet
+30.5%
$117.6M$153.5M

Current liabilities surged 30.5% — significant near-term obligations; verify ability to meet short-term debt.

Total Liabilities
Balance Sheet
+17.5%
$208.5M$245.0M

Liabilities increased 17.5% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-02-13
PRIOR — 2025-02-13
ADDED
As of January 31, 2026, the registrant had 117,673,382 shares of Class A common stock, $0.00001 par value per share, outstanding and 10,078,872 shares of Class B common stock, $0.00001 par value per share, outstanding.
Our revenue was $642.8 million and $610.8 million for the years ended 2025 and 2024, respectively, representing a year-over-year increase of 5%.
We generated net losses of $43.5 million and $182.6 million for the years ended 2025 and 2024, respectively.
In the years ended December 31, 2025 and 2024, we sold 1,007 and 1,073 instruments and 424,000 and 357,100 consumable reactions, respectively.
The Chromium portfolio enables high-throughput analysis of individual biological components.
+7 more — sign up free →
REMOVED
As of January 31, 2025, the registrant had 108,245,008 shares of Class A common stock, $0.00001 par value per share, outstanding and 14,056,833 shares of Class B common stock, $0.00001 par value per share, outstanding.
s expectations regarding our plans, objectives, goals, beliefs, business strategies, results of operations, financial position, sufficiency of our capital resources, business outlook, future events, business conditions, key business metrics and key factors affecting our performance, gross margin trends, expected future investments including anticipated capital expenditures, anticipated size of market opportunities and our ability to capture them, expected uses, performance and benefits of our products and services, business trends and other information.
Our revenue was $610.8 million and $618.7 million for the years ended 2024 and 2023, respectively, representing a year-over-year decrease of 1%.
We generated net losses of $182.6 million and $255.1 million for the years ended 2024 and 2023, respectively.
In the years ended December 31, 2024 and 2023, we sold 1,073 and 1,336 instruments and 357,100 and 347,000 consumable reactions, respectively.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →